Balchem (BCPC) Q2 FY26 earnings call: the analyst Q&A

Earnings call· Jun 2026 (Q2 FY26)· Materials· Jul 31, 2026

Source: earnings call transcript

Executive summary

Balchem Q2 FY26 — Record Performance Driven by Broad-Based Growth

Balchem delivered record financial results in Q2 FY26, driven by healthy, broad-based growth across all three segments and strong execution of strategic initiatives. The company strengthened its financial flexibility through a credit facility refinancing and continued capital returns, while maintaining momentum in market penetration and innovation despite higher input costs.

Highlights

Record quarterly consolidated sales of $284 million, an increase of 11.2% versus prior year.
Record quarterly adjusted EBITDA of $78 million, an increase of 12.6%.
Record quarterly adjusted net earnings of $48 million, an increase of 15.7%, translating to $1.49 per diluted share, up 17.3%.
Achieved 28th consecutive quarter of year-over-year growth in adjusted EBITDA.
Refinanced revolving credit facility, increasing borrowing capacity from $550 million to $650 million and extending maturity to 2031.

Concerns

Experienced higher input costs related to the conflict in the Middle East, which were partially offset by mitigating actions and operating leverage.

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Human Nutrition & Health Driven by growth in both Nutrient business and Food Ingredients and Solutions businesses, supported by consumer demand for healthier nutritional solutions. Adjusted earnings from operations growth: 10.9%	$177 million	10%	—	Adjusted earnings from operations: $46 million
Animal Nutrition & Health Increase driven by higher sales in both monogastric and ruminant businesses, continued adoption of encapsulated ruminant and protected nutrient technologies, and improved European monogastric business due to EU antidumping duties. Adjusted earnings from operations growth: 47.7%Ruminant portfolio growth: 20% (volume-driven)	$64 million	15%	—	Adjusted earnings from operations: $6 million
Specialty Products Driven by healthy growth in both Performance Gases and Plant Nutrition businesses, supported by favorable market positions and disciplined execution. Adjusted earnings from operations growth: 12.1%	$41 million	8.9%	—	Adjusted earnings from operations: $14 million

Risks & headwinds

Higher input costs Q2 FY26

higher input costs

Mitigation:mitigating actions and growth-driven operating leverage

Increased effective tax rate Q2 FY26

22.8% vs 21.9% prior year

Mitigation:N/A

Higher compensation-related costs Q2 FY26

operating expenses up to $44 million from $42 million

Mitigation:N/A

What to watch in Q3 FY26

MD Anderson/MIT Choline Study Publication

Next couple of months

Current Study completed, expected to be published in next couple of months

Target Publication of results

Why it matters

Potential for significant scientific validation of choline's cognitive benefits, especially for Alzheimer's/dementia, which could drive market penetration and demand.

The one that I am excited about and unfortunately, I don't have a an update today, but I'm very excited about this 1 that I've talked about in the past, and that's the MD Anderson University of Texas MIT, a pilot clinical study that has people in the study that have the APOE4 gene, which is really the gene that leads to Alzheimer's... we do expect that, that study should be published in the next couple of months.

Find out whether BCPC delivers this. Inve re-checks your case every morning.

Q&A highlights

How does Balchem decide which new nutrients to invest in, considering science, differentiation, and market penetration, and whether to develop internally or acquire?

Ted Harris explained that product selection is based on strong science, differentiation (e.g., encapsulated K2), and market penetration potential for niche products. The decision to build or buy depends on proximity to core technology; for example, OptifolinPlus (choline-based) was internal with external support, while K2 (different technology) was an acquisition.

“Certainly, 1 thing we start with is the science. We want to make sure there is already good existing sound science behind the the products that we're bringing in... And then kind of as you touched on, I think it's the -- what is our point of differentiation that's going to make our product different and more special...”

asked by Bob Labick · answered by Theodore Harris

2 min read 7 chapters

Detailed narrative

Overall Performance and Strategic Execution

Balchem achieved record quarterly consolidated sales, adjusted EBITDA, and adjusted net earnings, marking its 28th consecutive quarter of year-over-year adjusted EBITDA growth. This performance was attributed to broad-based growth across all segments, ongoing market penetration of specialty nutrients, and alignment with "better-for-you" trends in food and nutrition. The company also focused on strategic growth initiatives and disciplined capital allocation.

Human Nutrition & Health (HNH) Segment Highlights

The HNH segment delivered very strong results with record sales of $177 million, up 10%, and record adjusted earnings from operations of $46 million, up 10.9%. This growth was fueled by solid demand in both the Nutrient business and Food Ingredients and Solutions, benefiting from increased interest in supplementation and healthier, nutrient-dense products. The segment's differentiated ingredients and formulation expertise position it well for continued expansion.

Animal Nutrition & Health (ANH) Segment Performance

The ANH segment saw sales increase by 15% to $64 million, with adjusted earnings from operations up 47.7% to $6 million. Growth was driven by expanding adoption of precision release ruminant and protected nutrient technologies in dairy, stable U.S. monogastric business, and significant improvement in the European monogastric business following the implementation of EU antidumping duties. The ruminant portfolio, specifically, grew by approximately 20% year-over-year, primarily volume-driven.

Specialty Products Segment Growth

Specialty Products achieved record quarterly sales of $41 million, an 8.9% increase, and record adjusted earnings from operations of $14 million, up 12.1%. This segment's healthy, profitable growth was supported by strong performance in both Performance Gases and Plant Nutrition businesses, benefiting from favorable market positions and disciplined execution.

Capital Allocation and Financial Flexibility

Balchem enhanced its financial flexibility by refinancing its revolving credit facility, increasing borrowing capacity from $550 million to $650 million and extending maturity to 2031. The company also repurchased approximately $29 million of common stock in the quarter, contributing to $114 million in repurchases over the trailing 12 months, demonstrating a commitment to shareholder value.

Product Development and Clinical Studies

The company continues to invest in clinical studies to support its product portfolio, with 20-25 ongoing studies at any given time. Recent studies include those on Optifolin+, K2 Vital, and VitaCholine. A highly anticipated pilot clinical study with MD Anderson, University of Texas, and MIT, investigating high doses of choline for Alzheimer's and dementia in APOE4 gene carriers, has completed and is expected to be published in the next couple of months.

Marketing and Consumer Engagement

Balchem has significantly invested in marketing, particularly for Human Nutrition & Health, establishing a scalable "always-on" consumer engagement model. This involves omnichannel marketing, influencer engagement, consumer PR, and sports partnerships, generating over 1 billion consumer impressions. Marketing efforts are dynamically shifted to target evolving consumer behaviors, such as GLP-1 users for nutrient-rich snacks and specific sports partnerships.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.